DIRS.INFO The most relevant business & tech news

☆ David Einhorn to speak as the priciest market in decades gets even pricier postelection
▼ + stars: | 2024-11-12 | by ( Yun Li | ) www.cnbc.com time to read: +1 min

Hedge fund investor David Einhorn's cautious stance all year made his performance suffer as he navigated what he believes is the priciest stock market of his career at Greenlight Capital. Einhorn's hedge fund returned just 9% in 2024 through the end of the third quarter, net of fees and expenses. The high-profile investor said he's neither calling the market a bubble nor being outright bearish, but sky-high prices caused him to be conservatively positioned. It is, by many measures, the most expensive stock market that we have seen since the founding of Greenlight," Einhorn said in the latest investor letter last month. Investors will be interested to hear if he's still finding any values.

Persons: David Einhorn's, he's, Einhorn, Greenlight, Einhorn postelection, Viatris Organizations: Greenlight, Alpha, Trump Locations: Einhorn's, Greenlight, New York City

☆ This under-the-radar drug stock is undergoing a long-term turnaround, according to the charts
▼ + stars: | 2024-07-29 | by ( Katie Stockton | ) www.cnbc.com time to read: +7 min

—Katie Stockton with Will Tamplin Access research from Fairlead Strategies for free here . Fairlead Strategies Disclaimer: This communication has been prepared by Fairlead Strategies LLC ("Fairlead Strategies") for informational purposes only. Securities, investment products, other financial products or strategies discussed herein may not be suitable for all investors. The recipient of this information must make its own independent decisions regarding any securities, investment products or other financial products mentioned herein. This material is not to be reproduced or redistributed absent the written consent of Fairlead Strategies.

Persons: drugmaker, VTRS, Katie Stockton Organizations: CNBC, NBC UNIVERSAL, Fairlead, CNBC Pro, Securities

☆ These stocks were analysts' top picks for 2024. How they are doing nearly 3 months in
▼ + stars: | 2024-02-27 | by ( Pia Singh | ) www.cnbc.com time to read: +3 min

Now, we're tracking how well the analysts' picks have performed just three months into the new year. About 93% of analysts surveyed by LSEG hold a buy rating on Nvidia and have an average price target of $832.52. Warner Bros. Shares of Warner Bros. are down nearly 25% in the new year, and have lost about 45% over the past 12 months. Further, Warner Bros. did not give free cash flow guidance for 2024.

Persons: drugmaker Viatris, David Einhorn, Einhorn, Max Organizations: Dow Jones Industrial, CNBC, Nvidia, drugmaker, Pfizer, Warner Bros, APA Corp, Halliburton, Caesars Entertainment Locations: LSEG

☆ Goldman says these types of dividend stocks are the best to own in wake of big Meta payout news
▼ + stars: | 2024-02-12 | by ( Sarah Min | ) www.cnbc.com time to read: +3 min

For investors, that suggests opportunity in certain dividend stocks, Kostin wrote. Since late 2022, Goldman Sachs' Dividend Yield and Growth basket (GSTHDIVG), a 50-stock, equal-weighted basket of stocks with high trailing dividend yield and high anticipated dividend growth, has outperformed the equal-weighted S & P 500 by 3 percentage points. As of October, here are some of the stocks in the firm's dividend yield and growth basket. Verizon Communications Communication services stock Verizon Communications is a constituent in the dividend growth basket. Other stocks in Goldman's dividend growth basket include Best Buy , Conagra Brands and Devon Energy .

Persons: Goldman Sachs, David J, Meta, Kostin, That's, Greenlight Capital's David Einhorn, Morgan Stanley, Simon Flannery, — CNBC's Michael Bloom Organizations: Facebook, Bank of America, Federal Reserve, Verizon Communications Communication, Verizon Communications, Verizon, Conagra Brands, Devon Energy Locations: Viatris

☆ Greenlight’s David Einhorn ends his buyers' strike, finds a few 'promising' new stocks
▼ + stars: | 2024-01-22 | by ( Yun Li | ) www.cnbc.com time to read: +3 min

"We ended our buyers' strike and found several promising new investments that we believe will help us in 2024," the hedge fund manager said in an investor letter dated Monday and obtained by CNBC. Einhorn had stopped building new stock positions at one point in the fourth quarter due to worries about intensifying geopolitical risks. Because of his conservative positioning, his hedge fund, particularly the short side, was hurt during 2023's strong year-end rally. Einhorn's hedge fund returned 22.1% in 2023, net of fees and expenses. His stellar track record made him one of the most followed hedge fund managers on Wall Street.

Persons: Capital's David Einhorn, Einhorn, he's, Greenlight, drugmaker, He's, CNBC's Leslie Picker Organizations: CNBC, Cornell grad, Greenlight Capital, Wall, Pfizer, Syensqo, U.S . Aerospace & Defense, Invesco Aerospace & Defense, P Aerospace & Defense Locations: Belgian, U.S

LONDON, March 2 (Reuters) - Drugmaker Viatris Inc (VTRS.O) warned on Thursday that it will stop selling some essential medicines in the UK that are already in short supply unless the British government makes changes to its voluntary medicines pricing agreement. If that level is exceeded, the government recoups the excess from suppliers of branded drugs. His colleague Viatris' Head of Europe Artur Cwiok named Germany and Portugal as countries where governments were weighing changes to drug pricing. If Viatris opted to leave that pricing scheme, it would have to pay a rate in the statutory scheme the government says will rise to 27.5%. Pharma companies AbbVie Inc (ABBV.N) and Eli Lilly and Co (LLY.N) withdrew from the pricing scheme in January.

Search resuls for: "drugmaker Viatris"

6 mentions found